Repligen has tweaked its guidance in the wake of diminishing COVID-related orders but remains positive going forward due to a “very strong order book” for its base business. For the first quarter 2022, Repligen Corporation reported record revenue of $206.4 million, 45% up on the same period last year. Despite this, the bioprocess vendor has reduced its full year guidance by 4% from $800-$830 million to $770-$800 million due to the fall in COVID-related demand, something expected to continue throughout…

Sanofi has teamed with Formula 1 racing team McLaren to optimise manufacturing efficiencies within its network. The multiyear deal will see Sanofi’s Industrial Affairs team benefit from McLaren Racing team’s digital and analytical expertise tto achieve excellence in manufacturing operations. “Analysis of losses, modelling and simulation of production line scheduling, and specifically product change-overs, will be key areas to maximise performance in Sanofi manufacturing sites,” McLaren said in a press release. Both Sanofi and McLaren Racing “operate in a truly…

MilliporeSigma says the addition of the MAST (Modular Automated Sampling Technology) platform will help its customers optimize their bioprocesses and speed up development time. Lonza is offloading the platform to bioprocess vendor and fellow contract manufacturer MilliporeSigma – the life sciences service division of Germany’s Merck – for an undisclosed fee. The technology provides biomanufacturers near real-time sampling and analysis of bioreactors, the results of which can be used to deliver a range of analytical devices measuring titer, metabolites, and…

Synthetic biology company Evonetix has achieved enzymatic DNA synthesis capability with its thermally controlled synthesis chemistry, allowing the production of scarless DNA sequences. Evonetix is aiming to bring semiconductor technology to DNA synthesis and claims it has achieved enzymatic DNA synthesis through its thermally controlled synthesis chemistry, which is part of a three-year development program supported by Innovated UK and Durham University. The firm said the results demonstrate that its semiconductor array-based platform is compatible with enzymatic and chemical DNA…

Twist Bioscience reported a robust first quarter, having overcome a gene production issue last year that led a temporary halt in supply. For the first quarter fiscal year 2022, DNA synthesis firm Twist Bioscience reported revenues and orders of $42 million and $49.6 million, up 50% and 48% year-on-year, respectively. This included around $13.5 million in gene production for Twist’s partner with SynBio, a deal inked in 2017 that sees the firm manufacture synthetic DNA up to 3.2 kilobases in…